Nevro initiated at UBS

Nevro initiated with a Sell at UBS. UBS analyst Matthew Taylor initiated Nevro with a Sell rating and $35 price target, calling the stock a Top Sell. Taylor noted that Nevro’s HF10 therapy has “changed the face of neuromod,” but added that it has also “spurred competition from large, entrenched players.”
https://thefly.com/landingPageNews.php?id=2828767